Business Description

Business Description

Development of first-in-class
small molecular drugs

KinoPharma discovers, researches and develops first-in class small molecular drugs for the disorders with unmet medical needs in optimal administration required for the disease, including systemic and local administration.
We target attractive and unexplored market areas by providing first-in-class drugs. At the same time, taking the advantage of small molecular drugs and also taking into account scalable marketability, we aim to provide drugs into emerging and developing countries where medical demand is expected to increase in the shortest future at a cost that can be shared with patients in need.

Joint research and development
with Kyoto University

Our Kyoto Laboratory is located at the "Innovation Hub Kyoto" operated by Kyoto University, and conducts research and development with various supports provided by Kyoto University Medical Science and Business Liaison Organization (KUMBL). Furthermore, we have established a system of research and development which combines the wisdom of the academia and the speed of a biotech company, including the clinical studies led by medical doctors from Kyoto University based on the joint development agreement.

Business model

In recent years, about 60% of the new drugs approved by the FDA has been reported to be the product of academia-originated discovery. The direct involvement of academia in drug discovery was not as active in Japan; however, as seen in the example of Dr. Tasuku Honjo (Distinguished Professor of Kyoto University), a Nobel laureate in medicine and physiology in 2018, leading to the development of new drugs that changed the concept of cancer treatment, the style of drug discovery where academia plays a leading role is starting to produce distinctive results. We have introduced this academia-originated discovery and activated the organizational capability and strength to establish a system that facilitates basic research, preclinical studies, and clinical studies in a speedy manner. In addition, the candidate products are licensed to major pharmaceutical companies at appropriate timing to be escalated to market, thereby creating a business model that allows more opportunities for discovery of new drugs through the division of roles.